

AHSR 2023 Conference Schedule

Activity by day	Time	Location
<u>Day 1 – October 18, 2023 – Wednesday</u>		
<u>Registration opens</u>	8:00 to 12:00 PM	Verizon 121
<p><u>Pre-conference workshops</u></p> <p>Addiction Health Services Research at NIH: Workshop for Early Career Investigators” (Tisha Wiley, PhD & Laura Kwako, PhD)</p> <p>Using Population Claims Data for Substance Use Policy and Health Services Research (Yuhua Bao, PhD & Jake Morgan, PhD).</p> <p>Optimizing the Adaptation and Personalization of SUD Services: Innovations in Intervention and Experimental Designs (Inbal Billie Nahum-Shani, PhD, Daniel Almirall, PhD, Susan A. Murphy, PhD, & Linda M. Collins, PhD).</p>	1:00 to 2:30 PM	<p>Verizon 215</p> <p>Verizon 225</p> <p>Verizon 315</p>
<u>Afternoon break</u>	2:30 to 3:00 PM	Verizon Gallery
<p><u>Pre-conference workshops</u></p> <p>Conducting Medicaid-Related Research – Rationale, Priorities, Challenges, and Opportunities (Maureen Stewart, PhD, Christina Andrews, PhD, Julie Donohue, PhD).</p> <p>Navigating the Myriad of Analytic Choices for Policy Evaluation Studies (Megan Schuler, PhD, MS, Rosanna Smart, PhD, MA, Beth Ann Griffin, PhD, SM).</p> <p>Leveraging Implementation Science in Your Research and in Your Career (Mark McGovern, PhD, MA, Sara Becker, PhD, Cecelia Calhoun, MD, MPHS, MBA, Hélène Chokron Garneau, PhD, MPH, & Lori Ducharme, PhD).</p>	3:00 to 4:30 PM	<p>Verizon 215</p> <p>Verizon 225</p> <p>Verizon 315</p>
<u>Break</u>	4:30 to 5:00 PM	Gallery Event
<u>Opening reception and poster session</u>	5:00 to 6:00 PM	Verizon 121

Activity by day	Time	Location
Day 2 – October 19, 2023 – Thursday		
Breakfast / Welcome <ul style="list-style-type: none"> • **Announce Early Career** @ 7:30 AM • Poster setup at 7:00 AM to 10:45 AM 	7:00 to 8:00 AM	Main Lobby & Gallery Event x 2
<u>Plenary 1</u> Title: Pending Speaker: Tanzeem Choudhury, Ph.D. Affiliation: Cornell University	8:00 to 9:00 AM	Verizon 121
<u>Scientific break-out session</u> Symposium 1 - Economic Analyses Within the HEAL Prevention Cooperative: Implementation Costs and Financing Considerations Symposium 2 - Data-Driven Decision Making for Intervention Selection and Monitoring to Prevent Opioid Overdose Deaths, the HEALing Communities Study Case Symposium 3 - Mobile Health (mHealth) Interventions for Alcohol Use Disorder Symposium 4 - Implementing Collaborative Care for Co-Occurring Disorders: Implementation Outcomes from Four Clinical Trials	9:15 to 10:30 AM	Verizon 215 Verizon 225 Verizon 315 Verizon 121
<u>Break</u>	10:30 to 10:45 AM	Gallery Event x 2
<u>Scientific break-out session</u>	10:45 to 12:00 PM	

Activity by day	Time	Location
<p>Symposium 5 - Optimizing Multicomponent Interventions to Accomplish a Strategic Balance of Effectiveness and Ready Implementability: Latest Advances in the Multiphase Optimization Strategy</p> <p>Symposium 6 - Results from the First NIH-Funded State-Based Analyses of Medical Marijuana Uptake</p> <p>Symposium 7 - Equity Issues in Treatment for Alcohol and Opioid Use Disorders: Identifying Disparities and Policy Levers to Close the Gap</p> <p>Symposium 8 - Advances in Using the Global Appraisal of Individual Needs (GAIN) to Improve Measurement-Based Practices</p>		<p>Verizon 215</p> <p>Verizon 225</p> <p>Verizon 315</p> <p>Verizon 121</p>
<p><u>Lunch and poster session</u></p>	<p>12:00 to 1:45 PM</p>	<p>Gallery Event x 2 (2nd floor gallery & 3rd floor gallery space)</p>
<p><u>Scientific break-out session</u></p> <p>Symposium 9 - Maximizing Medicaid's Potential to Improve Access to Substance Use Disorder Treatment</p> <p>Symposium 10 - Medications for Opioid Use Disorders in Problem-Solving Courts: Using Implementation Science to Improve Access to Treatment</p> <p>Symposium 11 - Medications to treat opioid use disorder in jail: Qualitative findings on implementation from the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)</p> <p>Oral Presentation 1 - Cannabis and Tobacco</p>	<p>2:00 to 3:15 PM</p>	<p>Verizon 215</p> <p>Verizon 225</p> <p>Verizon 315</p> <p>Verizon 121</p>
<p><u>Break</u></p>	<p>3:15 to 3:30 PM</p>	<p>Gallery Event x 2</p>
<p><u>Scientific break-out session</u></p> <p>Oral Presentation 2 - Miscellaneous</p>	<p>3:30 to 4:45 PM</p>	<p>Verizon 215</p>

Activity by day	Time	Location
Oral Presentation 3 – Policy Oral Presentation 4 – Costing Oral Presentation 5 – Social Support		Verizon 225 Verizon 315 Verizon 121
<u>Plenary 2</u> Title: Leveraging Data to Understand and Guide Addiction Services Across New York State Speaker: Chinazo Cunningham, MD, MS Affiliation: Albert Einstein College of Medicine	5:00 to 6:00 PM	Verizon 121
<u>Day 3 – October 20, 2023 – Friday</u>		
<u>Breakfast</u>	7:00 to 8:00 AM	Main Lobby & Gallery Event x 2
<u>Plenary 3</u> Title: NIH Priorities for Addiction Health Services Research Speakers: Laura Kwako, PhD and Carlos Blanco, MD, PhD, MS Affiliation: NIH and NIDA	8:00 to 9:00 AM	Verizon 121
<u>Scientific break-out session</u> Oral Presentation 6 – Adolescent and Young Adults Oral Presentation 7 – COVID-19 Oral Presentation 8 – Methods/Modeling Oral Presentation 9 – Health Equity/Disparities Oral Presentation 10 – Health Equity/Disparities Oral Presentation 11 – Alcohol-Use Oral Presentation 12 – Social Perceptions/Stigma	9:15 to 10:30 AM	Verizon 215 Verizon 225 Verizon 315 Verizon 121 TATA 131 TATA 141 TATA 151
<u>Break</u>	10:30 to 10:45 AM	Gallery Event x 2

Activity by day	Time	Location
<u>Scientific break-out session</u> Oral Presentation 13 – Medicare Oral Presentation 14 – Medicaid Oral Presentation 15 – MOUD Oral Presentation 16 – MOUD Oral Presentation 17 – Medical Providers Oral Presentation 18 – State-specific Oral Presentation 19 – Harm Reduction	10:45 to 12:00 PM	Verizon 215 Verizon 225 Verizon 315 Verizon 121 TATA 131 TATA 141 TATA 151
<u>Prep (remove seating)</u>	12:00 to 12:30 PM	Verizon 121
<u>Poster Setup</u>	12:30 – 1:00 PM	Verizon 121
<u>Lunch</u>	12:30 to 1:00 PM	Gallery, outside seating
<u>Poster Session</u>	1:00 – 2:15 PM	Verizon 121
<u>Conclusion of Conference</u>	2:15 to 3:00 PM	

Symposium

Symposium Group 1: Economic Analyses Within the HEAL Prevention Cooperative: Implementation Costs and Financing Considerations - Thursday (9:15-10:30AM) in Room 215 *Panel Introduction by Kathryn McCollister*

#	Primary Presenter	Presentation Title
1	Margaret R. Kuklinski	Investing in Interventions to Prevent Opioid Use Disorder in Adolescents and Young Adults: Start-up Costs from NIDA's HEAL Prevention Initiative
2	Diana Bowser	Start-Up and Implementation Costs for the Trust Based Relational Intervention: Findings from NIDA's HEAL Prevention Initiative
3	Don Ekanayake	Financing Substance Use Prevention in the United States in Healthcare, Justice, and Educational Settings
4	Adam Vose-O'Neal	Police assisted diversion in Albany, NY: A qualitative evaluation of facilitators and barriers to program success

Symposium Group 2: Data-driven decision-making for intervention selection and monitoring to prevent opioid overdose deaths, the HEALing Communities Study Case - Thursday (9:15-10:30AM) in Room 225

#	Primary Presenter	Presentation Title
1	Peter Balvanz	Data-driven decision making to prevent opioid overdose deaths: Steps to access, visualize, and engage coalitions with data to inform intervention selection
2	Sarah Kosakowski	Engaging Community-Based Organizations and Community Coalition Members in Process Evaluation with Web-based Monitoring Reports
3	Jane Carpenter	Engaging an urban Massachusetts community in Data Walks to understand service gaps and opportunities to prevent opioid overdose deaths
4	Carolyn Damato-McPherson	Engaging People with Lived Opioid Use Experience from Rural Massachusetts in Photovoice to Understand Factors Fueling the Local Opioid Epidemic

Symposium Group 3: Mobile Health (mHealth) Interventions for Alcohol Use Disorder - Thursday (9:15-10:30AM) in Room 315

#	Primary Presenter	Presentation Title
1	Qiang Xie	Adapting an mHealth Intervention for Alcohol Use Disorder Based on Stakeholder Feedback
2	Linda S. Park	A mixed methods usability test of a digital health app for patients with alcohol-associated liver disease: Results of a pilot study
3	Xiang Li	A cost-effectiveness analysis of telemedicine and mobile health interventions to support continuing care for patients receiving treatment for alcohol use disorder
4	Ming-Yuan Chih	Does human touch improve an mHealth system for alcohol-related harm-reduction for mild to moderate Alcohol Use Disorder?: Study Design and Preliminary Results of a three-arm randomized clinical trial

Symposium Group 4: Implementing Collaborative Care for Co-Occurring Disorders: Implementation Outcomes from Four Clinical Trials - Thursday (9:15-10:30AM) in Room 121

#	Primary Presenter	Presentation Title
1	Katherine E. Watkins	The CLARO Clinical Trial: Implementing Collaborative Care for Opioid Use Disorders with Co-occurring Depression and/or PTSD in low-resource settings
2	Lynn L. DeBar	The MICARE Study: Implementation Strategies, Opportunities, and Unique Challenges of an Encouragement Trial Approach
3	David Mandell	The Whole Health Study: Strategies for Implementation and Sustainment Success
4	Tianna Herman	Factors Affecting Implementation and Prescribing Medications for Opioid Use Disorder: A Community-based Systems Analysis

Symposium Group 5: Optimizing multicomponent interventions to accomplish a strategic balance of effectiveness and ready implementability: Latest advances in the multiphase optimization strategy - Thursday (10:45-12:00PM) in Room 215

#	Primary Presenter	Presentation Title
1	Linda M. Collins	An intervention optimization perspective on building multicomponent interventions: challenges, opportunities, and required shifts in thought
2	Jillian Strayhorn	Applying decision analysis for intervention value efficiency to make decisions about candidate intervention components in the multiphase optimization strategy: An empirical example from HIV care
3	David Vanness	Decision analysis for intervention value-efficiency and cost-effectiveness analysis of multicomponent interventions: different tools for different decisions
4	Benjamin Enns	Evaluating the long-term population-level comparative effectiveness of buprenorphine/naloxone versus methadone in British Columbia, Canada

Symposium Group 6: Results from the First NIH-funded State-based Analyses of Medical Marijuana Uptake - Thursday (10:45-12:00PM) in Room 225

#	Primary Presenter	Presentation Title
1	Joseph W. Thompson	Statewide Assessment of Medical Marijuana Uptake and Healthcare Integration
2	Teresa Hudson	Who Qualifies for Medical Marijuana in Arkansas? Results from the First NIH-funded Population-level analysis of MMJ
3	Bradley C. Martin	A Statewide Examination of Medical Marijuana Purchasing Patterns by Authorized Medical Condition
4	Anthony Goudie	Impact of Medical Marijuana on Healthcare Utilization in PTSD Treatment

Symposium Group 7: Equity Issues in Treatment for Alcohol and Opioid Use Disorders: Identifying Disparities and Policy Levers to Close the Gap - Thursday (10:45-12:00PM) in Room 315

#	Primary Presenter	Presentation Title
1	Andrea Acevedo	Alcohol Treatment Utilization at the Intersection of Race, Ethnicity, Gender and Insurance Status
2	Michael William Flores	Medicaid Expansion and Racial/Ethnic Disparities in Medication for Opioid Use Disorder Among Adults Accessing Substance Use Treatment for Illicit Opioid Use
3	Rachel Sayko	Discontinuation of medications for opioid use disorder among commercially insured adults with and without traumatic brain injury
4	Maureen T. Stewart	Changes in Medication for Opioid Use Disorder Utilization by Race and Ethnicity among Medicaid Beneficiaries in Washington State, 2015 to 2019

Symposium Group 8: Advances in Using the Global Appraisal of Individual Needs (GAIN) to Improve Measurement-based Practices - Thursday (10:45-12:00PM) in Room 121

#	Primary Presenter	Presentation Title
1	Rebecca M Durham	Utility of the Global Appraisal of Individual Needs Quick Version 4 for Diagnosing Substance Use Disorders in Adolescents
2	Siara I. Sitar	The Reliability of the Global Appraisal of Individual Needs Quick Version 4 (GAIN-Q4) in ASAM Dimensions and Level of Care Placement
3	Barbara D. Estrada	Screen4Success.org: A Dynamic Website for Providers to Screen Individuals for Substance Use, Health and Wellness and Refer to Relevant Resources
4	Beth Ann Griffin	Estimating Policy Effects using Lagged Outcome Values to Impute Counterfactuals

Symposium Group 9: Maximizing Medicaid's Potential to Improve Access to Substance Use Disorder Treatment - Thursday (2:00-3:15PM) in Room 215 *Panel Introduction by Colleen Grogan*

#	Primary Presenter	Presentation Title
1	Rebecca Morris	Substance Use Disorder Treatment Regulatory Policy in State Contractual Agreements with Medicaid Managed Care Plans
2	Lauren Peterson	State Coverage and Oversight Policies for Substance Use Disorder Treatment in Medicaid Managed Care
3	Amanda J. Abraham	Trends in State Medicaid FFS Benefits for Substance Use Treatment During the Opioid Crisis
4	Christina Andrews	Prior Authorization for Buprenorphine: The Role of Profit Status and Partisanship in Medicaid Managed Care

Symposium Group 10: Medications for Opioid Use Disorders in Problem-Solving Courts: Using Implementation Science to Improve Access to Treatment - Thursday (2:00-3:15PM) in Room 225

#	Primary Presenter	Presentation Title
1	Barbara Andraka-Christou	Factors Involved in Problem-Solving Court Decisions to allow medications for opioid use disorder
2	Ekaterina Pivovarov	Barriers and Facilitators to Collaboration between MOUD Agencies and Drug Courts: Findings from Qualitative Interviews with MOUD Providers
3	Lindsay Smith	Having a Steady Supply of Providers Increases Drug Court Utilization of MOUD
4	Pryce S. Michener	Diffusion of Medications for Opioid Use Disorder Treatment in Jail Settings: A Convergent Mixed Methods Study of Jail Staff Perspectives

Symposium Group 11: Medications to treat opioid use disorder in jail: Qualitative findings on implementation from the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN) - Thursday (2:00-3:15PM) in Room 315

#	Primary Presenter	Presentation Title
1	Claudia Santelices	Top Leadership Perspectives and Experiences with Jail-Based MOUD treatment: Preliminary Qualitative Findings from County Sheriffs
2	Elizabeth A. Evans	Diversion of medications to treat opioid use disorder: Reports from formerly incarcerated adults in Massachusetts
3	Warren J. Ferguson	Patient Perspectives of Jail-Based MOUD treatment: Views of individuals who have returned to community following incarceration
4	Bianca Y. Planas-García	Medications for Opioid Use Disorder (MOUD) Community Providers' Perspectives on Their Collaborations with Jails: A Qualitative Analysis
5	Thomas J. Stopka	Extended-release buprenorphine: Qualitative perceptions among people who received medication for opioid use disorder in jail

Oral Presentations

Oral Presentations 1: Cannabis and Tobacco - Thursday (2:00-3:15PM) in Room 121

#	Primary Presenter	Presentation Title
1	Jayani Jayawardhana	Impact of Cannabis Laws on Hospitalizations for Asthma
2	Felipe Lozano-Rojas	The Effect of Cannabis Laws on Access to Pain Medications Among Commercially Insured Patients in the U.S.
3	Juliet Edgcomb	Detecting Trends in Cannabis Use and Cannabis Use Disorder among Patients in a Large Academic Health System Using Electronic Health Record Data
4	Sarah Gutkind	Association between financial strain and changes in cigarette use among middle-aged and older adults in the United States, 2018-2020
5	Caro Maltz	Pilot Study of EMA Delivered Attentional Retraining for Postpartum Smoking Relapse

Oral Presentations Group 2: Miscellaneous - Thursday (3:30-4:45PM) in Room 215

#	Primary Presenter	Presentation Title
1	Jenny Becan	Overview of three clinical trials within the Justice Community Opioid Innovation Network: Workgroup approaches for promoting service access improvement
2	Tess Drazdowski	Juvenile Probation Officers' Experiences Delivering Family-Based Contingency Management for Youth Substance Use: Task-Shifting to Increase Services in Rural Communities
3	Verena E. Metz	Prescription Opioid Dose Reductions and Potential Adverse Events: a Multi-site Study in Eight U.S. Health Systems
4	Hildi J. Hagedorn	Advancing Pharmacological Treatments for Opioid Use Disorder: Outcomes of An Implementation Trial in Eight Veterans Health Administration Facilities

Oral Presentations Group 3: Policy - Thursday (3:30-4:45PM) in Room 225

#	Primary Presenter	Presentation Title
1	Huiru Dong	Impact of State Mandates of Naloxone Coprescription on Naloxone Prescription Dispensing in the United States
2	Sean Grant	ROMPER: The RAND/USC OPTIC Method for Policy Expert Ratings
3	Jonathan Purtle	A Tale of Two Taxes: Comparing Perceptions of the Implementation of Policies Earmarking Taxes for Behavioral Health Services in California and Washington
4	Danielle Good	Oregon Decriminalizes Drugs: Lessons from Local Implementation

Oral Presentations Group 4: Costing - Thursday (3:30-4:45PM) in Room 315

#	Primary Presenter	Presentation Title
1	Danielle Ryan	Micro-costing the implementation facilitation to promote emergency department-initiated buprenorphine with referral for opioid use disorder
2	Tyler Judge	Micro-Costing of CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy
3	Hannah Cheng	Considerations and strategies to estimate the total costs of implementing medications for opioid use disorder: A pragmatic microcosting approach
4	Jonathan Purtle	Implementation of the 988 Crisis Lifeline at the State-Level: Estimating Costs of Increased Call Demand at Lifeline Centers and Quantifying State Financing

Oral Presentations Group 5: Social Support - Thursday (3:30-4:45PM) in Room 121

#	Primary Presenter	Presentation Title
1	Mary B. Kleinman	Peer Recovery Specialist-Delivered Behavioral Activation Intervention Shifting Substance Use Stigma
2	Sam Jaros	A Mixed-Methods Analysis of Community Factors Influencing Acceptance of Medication for Opioid Use Disorder Services
3	Jasmin Choi	Does family support matter? The impact of support person attitudes toward MOUD on patient perceptions of support.
4	Arthur Robin Williams	How Conflict, Cohesion, and Social Support Affect Patients In Buprenorphine Treatment and their Families

Oral Presentations Group 6: Adolescent and Young Adults - Friday (9:15-10:30AM) in Room 215

#	Primary Presenter	Presentation Title
1	Kristyn Zajac	Prolonged Exposure and Contingency Management for Posttraumatic Stress and Substance Use Disorders in Emerging Adults: Results of a Pilot Trial
2	Michael Smoker	Disseminating Contingency Management for Adults and Adolescents with Substance Use Disorders across Indiana
3	Steven Tran	Characteristics associated with impaired driving and risky passenger behaviors among adolescents in driver education
4	Jayla French	Clinician Perspectives on Barriers and Facilitators to Providing Medications for Opioid Use Disorder for Adolescents in Indiana: A Qualitative Study

Oral Presentations Group 7: COVID-19 - Friday (9:15-10:30AM) in Room 225

#	Primary Presenter	Presentation Title
1	Shelby Steuart	Pediatric Opioid-Related Poisonings Before and During COVID-19
2	Samantha Young	"Would I have done that without a pandemic? Probably not": Perspectives of People Who Use Opioids and Prescribers on a Rapidly Developed Guidance Document for Prescribing Opioid Agonist Therapy in Ontario During the COVID-19 Pandemic
3	Lesley Harris	What Can We Learn from COVID-19 to Improve Opioid Treatment? Expert Providers Respond
4	Lillian Gelberg	Implementing Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Risky Drug Use in FQHC Primary Care Clinics in the COVID-19 Era: The QUIT-Mobile Study

Oral Presentations Group 8: Methods/Modeling - Friday (9:15-10:30AM) in Room 315

#	Primary Presenter	Presentation Title
1	Robert Heimer	Using system dynamics modeling to study temporal trends in opioid overdose response and linkage to medication for opioid use disorder in Connecticut
2	Nasim Sabounchi	Using Dynamic Modeling to Simulate and Evaluate Evidence-Based Practices for Reducing Opioid Morbidity and Mortality among Counties in New York State
3	Praveen Kumar	An Agent-based Model of Opioid Use Disorder and the Impact of Intervention Strategies
4	Ali Jalali	Addressing Electronic Health Records (EHR) Discontinuity in Substance Use Disorder Research: The Synthetic Shrinkage Estimation (SSE) Approach

Oral Presentations Group 9: Health Equity/Disparities - Friday (9:15-10:30AM) in Room 121

#	Primary Presenter	Presentation Title
1	Diane Hilderbrand	Racial Disparities in the Implementation of the California Hub and Spoke System
2	Thuy Nguyen	Racial and Ethnic Disparities in the Receipt of Medications for Opioid Use Disorder Following Emergency Department Visits for Opioid Overdose in the Medicaid Population
3	Huiru Dong	The Impact of CDC's Opioid Prescribing Guideline on Racial Disparities in Discontinuation of Opioid Treatment in the United States
4	Rachel Epstein	Disparities in medication initiation among females of reproductive age in Massachusetts with opioid use disorder

Oral Presentations Group 10: Health Equity/Disparities - Friday (9:15-10:30AM) in TATA Room 131

#	Primary Presenter	Presentation Title
1	Natalia Van Doren	Racial disparities in buprenorphine treatment for opioid use disorder across VA Healthcare System
2	Hannah Cheng	The IMAT-PC-E: A practical measure of health equity in addiction medication practice in primary care
3	Khadija Israel	The role of mandated treatment on expectant mothers: a propensity score approach.
4	Bryan R. Garner	Testing the incremental effectiveness of pay-for-performance to improve implementation of a motivational interviewing brief intervention for substance use disorders in HIV settings: Results of a cluster-randomized type 3 hybrid trial

Oral Presentations Group 11: Alcohol-Use - Friday (9:15-10:30AM) in TATA Room 141

#	Primary Presenter	Presentation Title
1	Brian Chan	Latino-white Disparities in Screening and Receipt of Medications for Unhealthy Alcohol Use in the OCHIN Network of Community Health Clinics
2	Joan S. Tucker	Reducing Alcohol Use Among Emerging Adults Experiencing Homelessness: 24-Month Outcomes from a Cluster Cross-Over Randomized Controlled Trial of AWARE
3	Adam Viera	Spatial associations between alcohol detection in opioid-involved overdose deaths and alcohol outlets
4	Jacob Tempchin	Emerging Adult Preferences for Receiving Brief Alcohol Interventions

Oral Presentations Group 12: Social Perceptions/Stigma - Friday (9:15-10:30AM) in TATA Room 151

#	Primary Presenter	Presentation Title
1	Marynia Kolak	A Multidimensional, Socio-ecological View of Access to Medications for Opioid Use Disorder: Associations of Access Among Persons Who Inject Drugs and the Rural Risk Environment
2	Alex Rains	"I would do anything but that": Attitudes towards sex work among rural people who use drugs
3	Kristen Regenauer	Siyakhana: A Stepped-Wedge Trial to Reduce Stigma Towards Substance Use Among Community Health Workers in TB/HIV Care in South Africa
4	Katherine Watkins	Using social norms to decrease post-surgical opioid prescribing: a cluster randomized trial

Oral Presentations Group 13: Medicare - Friday (10:45-12:00PM) in Room 215

#	Primary Presenter	Presentation Title
1	Ateev Mehrotra	Early experiences with Medicare's reimbursement for Opioid Treatment Program care, 2020-2022
2	Amanda Abraham	Introduction of Medicare Coverage in Opioid Treatment Programs: Findings from the First Year
3	Patience Moyo	Prevalence and Association of Opioid Use Disorder Diagnosis with Nonpharmacologic, Nonopioid, and Opioid Pain Treatment Receipt among Medicare Beneficiaries with Acute Low Back Pain
4	Hillary Samples	Buprenorphine after non-fatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries

Oral Presentations Group 14: Medicaid - Friday (10:45-12:00PM) in Room 225

#	Primary Presenter	Presentation Title
1	Yuhua Bao	Use of Medicaid-covered peer support services in 2019 by enrollees diagnosed with opioid use disorder across 28 US states
2	Peter Treitler	Association of emergency department buprenorphine receipt with subsequent treatment and outcomes among New Jersey Medicaid beneficiaries
3	Olivia Hinds	Pilot Study of Screening, Treatment, and Referral for Substance Use Disorder in Medicaid Health Homes
4	Peter Treitler	Emergency department-based peer support for opioid overdose survivors: Association of program participation with drug treatment initiation and outcomes

Oral Presentations Group 15: MOUD - Friday (10:45-12:00PM) in Room 315

#	Primary Presenter	Presentation Title
1	Kenzie Potter	Facilitators and Barriers to the Rapid Induction Procedure for Injectable Naltrexone in a large, multisite inpatient trial.
2	Brian Chan	Participant Reported Outcomes in Digitally-Provided Buprenorphine Treatment for Opioid Use Disorder Compared With Treatment as Usual Office-Based Treatment: an Observational Longitudinal Cohort Study
3	Yasna Rostam-Abadi	Utilization of Medication for Opioid Use Disorder for Hospitalized Patients at 6 New York City Public Hospitals with an Addiction Consult Service
4	Anjalee Sharma	Barriers to Substance Use Disorder Treatment for Emergency Department Patients During COVID-19

Oral Presentations Group 16: MOUD - Friday (10:45-12:00PM) in Room 121

#	Primary Presenter	Presentation Title
1	Anh Nguyen	Leveraging Data Linkages to Investigate Health Insurance Instability and Mortality among Patients Receiving Medications for Opioid Use Disorder
2	Marian Jarlenski	Medication for opioid use disorder and risk of overdose in the year after delivery
3	Arthur Robin Williams	Retention and Critical Outcomes among New Methadone Maintenance Patients Following Extended Take-Home Reforms
4	Rebecca Stewart	Organizational MOUD adoption lower among organizations who link out to external providers

Oral Presentations Group 17: Medical Providers - Friday (10:45-12:00PM) in TATA Room 131

#	Primary Presenter	Presentation Title
1	Rebecca Bilden	Examining Barriers to Buprenorphine Treatment for OUD: X Waiver Elimination and Increasing Support and Education for Providers
2	Paul Christine	Relaxing buprenorphine X-waiver training requirements did not generally increase prescribers or patients receiving treatment: Evidence from the Healing Communities Study
3	Jure Baloh	R3 supervisor strategy in substance use disorder treatment settings: a qualitative formative evaluation of provider perceptions in Arkansas
4	Bradley D. Stein	Factors Associated with High Volume Buprenorphine Prescribers

Oral Presentations Group 18: State-specific - Friday (10:45-12:00PM) in TATA Room 141

#	Primary Presenter	Presentation Title
1	Robert Heimer	Receipt of addiction treatment after non-fatal overdose and risk of subsequent overdose: a statewide retrospective cohort study
2	Miguel Antonio Estrada	Statewide Efforts to Address the Drug Overdose Crisis: Results from a Survey of Single State Agencies
3	Robert Heimer	A spatiotemporal analysis of the association between residential eviction and fatal overdose in Rhode Island
4	Shazia Hussain	Examining Changes in Program-level Substance Use Disorder Treatment Outcomes in New York State

Oral Presentations Group 19: Harm Reduction - Friday (10:45-12:00PM) in TATA Room 151

#	Primary Presenter	Presentation Title
1	Tse Yang Lim	Is there fentanyl in the stimulant supply? Spatiotemporal evidence from U.S. mortality data
2	Kelvin Wu	Knowledge is Power: Evaluating community drug checking services as a tool to combat British Columbia's toxic drug crisis
3	Czarina Behrends	Economic evaluations of establishing opioid overdose prevention centers in 12 North American cities: a systematic review
4	W. Alton Russell	Take-home naloxone for prescription opioid patients: a data-driven cost effectiveness analysis